Analyst Price Target is $140.00
▲ +1,128.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ALK-Abelló A/S in the last 3 months. The average price target is $140.00, with a high forecast of $140.00 and a low forecast of $140.00. The average price target represents a 1,128.07% upside from the last price of $11.40.
Current Consensus is
The current consensus among 3 polled investment analysts is to moderate buy stock in ALK-Abelló A/S. This Moderate Buy consensus rating has held steady for over two years.
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.